Aaron G.L. Fletcher

Aaron G.L. Fletcher (senior executive) discloses dealings in 8 companies, chiefly Lantern Pharma Inc., Cognition Therapeutics Inc and In8bio, Inc. Over a trading history stretching from 30 June 2021 to 17 June 2026, the count stands at 67 filings.

The open-market side counts 23 purchases for €8.4M alongside 28 sales for €826k. No amount is published for 1 filing, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 10 share grants and 1 option exercise.

In size, the median ticket on the buying side is €22k. 19 out of 23 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. Ninety days after publication, 19 purchases show a median change of -42.5%, with the price up in 16% of them. This is a record of the past, not a forecast.

The latest filing, published on 22 June 2026, reports a share grant in Cognition Therapeutics Inc. The clock since the last published purchase (30 June 2025) now reads 475 days. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.